Risvodetinib, a selective c-Abl kinase inhibitor, demonstrated acceptable safety and tolerability profiles in a 12-week phase 2a trial involving patients with early, untreated Parkinson's disease. The randomized, double-blind study represents the first human testing of targeting c-Abl kinase for neurodegeneration treatment. This approach builds on compelling preclinical evidence linking c-Abl activation to alpha-synuclein pathology and dopaminergic neuron death—hallmarks of Parkinson's progression. The kinase becomes hyperactivated in response to cellular stress and directly phosphorylates alpha-synuclein, promoting toxic protein aggregation. Previous animal studies using c-Abl inhibitors showed neuroprotective effects and reduced motor symptoms. However, translating kinase inhibitors from oncology to neurology presents unique challenges, particularly regarding blood-brain barrier penetration and long-term CNS effects. The safety focus of this trial, rather than efficacy endpoints, reflects the cautious approach needed when repurposing cancer drugs for chronic neurological conditions. While encouraging for future development, the study's brief duration and early-stage patient population limit conclusions about disease-modifying potential. Longer trials with motor and cognitive outcomes will determine whether c-Abl inhibition can meaningfully slow Parkinson's progression in the clinical setting.